EU approves Xgeva and throws Amgen a bone - one year's extra protection
This article was originally published in Scrip
The European Commission has approved Amgen's RANK ligand inhibitor Xgeva (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumours.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.